- Home
- ACRS vs REFI Comparison
ACRS vs REFI Comparison
Compare ACRS & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | REFI |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 255.6M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | REFI |
|---|---|---|
| Price | $3.19 | $11.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $9.75 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 3.1M | 129.8K |
| Earning Date | 02-23-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 17.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.69 |
| Revenue | $15,742,000.00 | ★ $54,287,847.00 |
| Revenue This Year | N/A | $13.69 |
| Revenue Next Year | N/A | $3.55 |
| P/E Ratio | ★ N/A | $7.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $11.62 |
| 52 Week High | $4.89 | $16.27 |
Technical Indicators
Market Signals| Indicator | ACRS | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 32.08 |
| Support Level | $3.25 | $11.66 |
| Resistance Level | $3.78 | $12.49 |
| Average True Range (ATR) | 0.25 | 0.24 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 13.52 | 7.23 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.